Skip to main
  1. Stocks
  2. Verastem
  3. Forecast
VSTM

Verastem (VSTM) Stock Forecast & Price Target

Verastem (VSTM) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Verastem is viewed positively because its approved AVMAPKI FAKZYNJA co-pack is already generating meaningful commercial traction, with 3Q26 revenue of $24.0M, up 114% Y/Y, and strong refill growth that suggests durable demand even as new patient starts were seasonally softer. The investment case is further strengthened by a well-funded balance sheet, with pro forma cash of $422.8M expected to support operations into 1H28, while the pipeline offers multiple value-driving shots on goal through VS-7375, including a 41% confirmed ORR in 22 previously treated PDAC patients and a 67% six-month PFS landmark. Despite competitive and timing risks, the company’s RAF/MEK and FAK biology, improving safety profile, and several expected data readouts in early 2027 support a favorable long-term fundamental outlook.

Bears say

Verastem is viewed negatively because its lead asset Avmapki Fakzynja lacks sizable, definitive randomized data, leaving commercial adoption and payer confidence uncertain despite the company’s late-stage oncology focus. The downside case suggests that if traction, efficacy, or safety disappoints, VSTM could trade near its net cash position with minimal pipeline value, underscoring how little fundamental support exists beyond the program itself. Additional pressure comes from the small LGSOC addressable population, potential difficulty enrolling patients, competitive intensity that could limit launch uptake, and early-stage expansion assets like G12D that remain unproven and in competitive spaces.

Verastem (VSTM) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.

Verastem (VSTM) Analyst Forecast & Price Prediction

Get the latest Verastem (VSTM) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Verastem (VSTM)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Verastem (VSTM) Forecast

Analysts have given Verastem (VSTM) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Verastem (VSTM) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Verastem (VSTM)


Verastem (VSTM) Analyst Forecast & Price Prediction

Get the latest Verastem (VSTM) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Verastem (VSTM)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover VSTM stock data and trends